about
Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Functional imaging in lung cancerPositron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MRReproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MRHow to study optimal timing of PET/CT for monitoring of cancer treatmentThe clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.PET/CT in therapy evaluation of patients with lung cancer.Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting.The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysis.Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma.How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study.Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer.Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma.PET/CT is a cost-effective tool against cancer: synergy supersedes singularityPositron emission tomography of incidentally detected small pulmonary nodules.Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments.A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma.Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial.PET/CT imaging in response evaluation of patients with small cell lung cancer.[Lung cancer--a technological challenge I. Diagnostics and staging].[Lung cancer--should positron-emission tomography be used?].[Positron emission tomography in the diagnosis of lung cancer].[Lung cancer--a technological challenge II. New approaches to treatment].Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients.Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals[Women and lung cancer--epidemiology, smoking and biology]PET-CT in preoperative staging of lung cancer[PET/MR scanning]A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients
P50
Q33850467-400085BF-ED96-4FC7-BF78-A4C597457A93Q35550676-F2DCE64A-6D95-49F6-914D-CB3100163B82Q35874704-D43C1829-8A05-49CD-919E-7857AFA5C5BCQ35986332-1E3286AC-8C59-4F20-B4D6-8EA49C0CFE74Q36295389-681AAC08-CF86-4752-BA9C-2444E8BA5418Q36337232-CAB488A6-D6D3-47D8-BBCD-D3EAFDB9ABF4Q37614753-03616241-A127-4981-A59F-0E0FCBAA0D20Q38202189-812AB2F4-E49E-4E20-AD9D-9B0CD1B20216Q38409078-310014B4-3783-4E0B-81B0-AA5E34EF5BAAQ38412675-8DECB900-2898-4459-9F77-9A967571CF29Q39481653-FCB60E9C-4669-4823-9404-6EE8ED2959E1Q40070631-A340C605-D946-4F50-BBA3-5622D06108ACQ40292903-3E563A65-EF92-455A-97E9-057039CF8C40Q40953865-9CEBA32C-C5BD-4491-999C-A0B57DAEFF1FQ41500273-22A12E29-064D-4B6D-8495-5CDECCB6FD07Q42388521-64E65B43-B7DD-4F7C-A179-09167F8B0DEEQ44827892-65F5192E-C7C0-4B90-92D4-03A03D4C475AQ47621899-B8769F39-2593-4094-8567-DC9D850BCB52Q47656762-51E9647E-B9ED-476A-AE0D-5B951067BF69Q49885260-BE542D15-1921-4739-A6CC-F1FEEA05A443Q49946981-CE4F1D55-41B5-4886-B6B1-FC3E47D89FE4Q53031802-622F2CF8-BBBF-4E3F-BEFD-056906DA39FAQ53066978-B809639D-0217-40F6-AB01-021732D14EBEQ53251677-1F6F9680-64BA-4601-B6DD-E5E3E746ED27Q53254546-07631FF8-8C1A-49F5-A941-7175F5370134Q53523846-9315D4C2-6B0C-4A9B-BAB4-7144105E9BCBQ53601683-7C5ECB20-E97C-49C4-874B-48278BA2E93CQ53616314-F368A868-CCAC-42AA-BB3A-47CD5BE96AF0Q53624498-B6D3D013-DDDD-46CA-88A4-C932C79626F9Q54529004-DF198500-059D-42DB-8A65-FF6A1AF70475Q54966312-151B2AD3-1BB4-410E-BDA0-07BBF92FE3C5Q57679641-C614051B-6408-41DA-B48D-090A72C65114Q79368529-B66558FF-C29F-4539-9D3A-FB84F168FA65Q83571353-15976883-E796-4EDA-990C-740F5DFDE80AQ83703443-FF3DD295-E6EC-4B26-A950-453D986C36E4Q89046074-70B7864F-4CE1-452E-9C8F-4C4A156C581B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Barbara M Fischer
@ast
Barbara M Fischer
@en
Barbara M Fischer
@es
Barbara M Fischer
@nl
Barbara M Fischer
@sl
type
label
Barbara M Fischer
@ast
Barbara M Fischer
@en
Barbara M Fischer
@es
Barbara M Fischer
@nl
Barbara M Fischer
@sl
prefLabel
Barbara M Fischer
@ast
Barbara M Fischer
@en
Barbara M Fischer
@es
Barbara M Fischer
@nl
Barbara M Fischer
@sl
P106
P21
P31
P496
0000-0002-6065-3375